McKesson Hit by Cyberattack; Hackers Claim Millions of Patient Records Stolen, Adding New Risk to Stretched Valuation

What happened

A prolific hacking group has claimed responsibility for last week's cyberattack on McKesson's systems, alleging the theft of millions of patient records. This development introduces a new operational and legal risk not previously emphasized in the DeepValue report, which focused on opioid litigation and valuation. While McKesson has not yet confirmed the breach's scope, the incident could trigger regulatory scrutiny, class-action lawsuits, and costly remediation, adding to the company's existing $5.7 billion litigation liabilities. The stock was already deemed overvalued at $825 with limited margin of safety, and this news is likely to pressure sentiment further. Investors should monitor for official disclosure and assess whether the breach affects core pharmaceutical distribution or the higher-margin oncology and technology platforms.

Implication

The cyberattack introduces a new vector of downside that the prior thesis did not fully price, potentially leading to near-term multiple compression and increased uncertainty. If the breach is confirmed as large-scale, McKesson may face regulatory fines under HIPAA, civil lawsuits, and remediation costs that could consume cash otherwise earmarked for buybacks, further pressuring EPS growth. Additionally, reputational damage could erode customer trust in its oncology and specialty platforms, which are central to its premium valuation. While the company's scale and financial resources provide some cushion, the event underscores the fragility of assuming benign tail risks at a time when the stock trades at ~32x trailing earnings. Until management quantifies the breach's financial and operational impact, investors should treat McKesson as a show-me story and avoid adding exposure.

Thesis delta

The cyberattack shifts the risk profile from primarily litigation and execution risk to include operational and data-security risk, which was not a central concern in the prior report. This event increases the probability of the bear case, as unforeseen cash outflows and reputational harm could undermine the oncology-led growth narrative. The thesis remains POTENTIAL SELL, but the cyber breach heightens the urgency to trim positions above $800 and wait for a lower entry or evidence that the incident is contained.